Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505200 | 1.00 | PLAU (0.45) | PLAUHRH3MAPK14MAPK13MAPK12 | |
| SCHEMBL25908403 | 0.91 | HRH3 (0.46) | PLAUHRH3MAPK14MAPK13MAPK12 | |
| SCHEMBL28375017 | 0.90 | PLAU (0.42) | PLAUHRH3MAPK14MAPK13MAPK12 | |
| SCHEMBL16896444 | 0.90 | HRH3 (0.45) | PLAUHRH3MAPK14MAPK13MAPK12 | |
| SCHEMBL28378947 | 0.86 | MAPK14 (0.42) | PLAUHRH3MAPK14MAPK13MAPK12 | |
| SCHEMBL30461103 | 0.86 | MAPK14 (0.42) | PLAUHRH3MAPK14MAPK13MAPK12 | |
| SCHEMBL16896607 | 0.84 | HRH3 (0.47) | HRH3 | |
| SCHEMBL29505292 | 0.84 | HRH3 (0.47) | HRH3 | |
| Hydrochloric Acid SCHEMBL29505368 | 0.84 | HRH3 (0.46) | HRH3 | |
| Hydrochloric Acid SCHEMBL16896479 | 0.84 | HRH3 (0.46) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414582-A1 | METHODS OF TREATING DISEASES AND DISORDERS | CURIS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4252853-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Oncology Limited (IN) | 2023-10-04 | — | — | EP | claimed |
| EP-4248212-A1 | METHODS OF TREATING DISEASES AND DISORDERS | Curis, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116710776-A | Methods of treating diseases and disorders | 柯里斯公司 | 2023-09-05 | — | — | CN | claimed |
| EP-3600270-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE ONCOLOGY LTD (IN) | 2023-06-14 | — | — | EP | claimed |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | claimed |
| WO-2022108996-A1 | METHODS OF TREATING DISEASES AND DISORDERS | CURIS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| CN-111362966-B | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-09-23 | — | — | US | claimed |
| EP-3466955-B1 | METHOD OF PREPARING OXAZOLO[4,5-B]PYRIDINE AND THIAZOLO[4,5-B]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS FOR TREATING CANCER | AURIGENE DISCOVERY TECH LTD (IN) | 2020-12-16 | — | — | EP | claimed |
| CN-106456619-B | Bicyclic heterocyclic derivatives as IRAK4 inhibitors | 奥列基因发现技术有限公司 | 2020-03-27 | — | — | CN | claimed |
| EP-3600270-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Discovery Technologies Limited (IN) | 2020-02-05 | — | — | EP | claimed |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | CURIS, INC. | 2019-05-09 | — | — | US | claimed |
| EP-3466955-A1 | METHOD OF PREPARING OXAZOLO[4,5-B]PYRIDINE AND THIAZOLO[4,5-B]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS FOR TREATING CANCER | Aurigene Discovery Technologies Limited (IN) | 2019-04-10 | — | — | EP | claimed |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| WO-2018178947-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-10-04 | — | — | WO | claimed |
| EP-3094329-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2018-09-26 | — | — | EP | claimed |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | claimed |
| US-9732095-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-15 | — | — | US | claimed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414582-A1 | METHODS OF TREATING DISEASES AND DISORDERS | IRAK4, IRAK3, IRAK2 | PLAU 1229/4885HRH3 2770/4885MAPK14 3629/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | PLAU 3662/4885HRH3 2239/4885MAPK14 145/4885 |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | PLAU 4000/4885HRH3 2293/4885MAPK14 193/4885 |
| US-20210290628-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, FLT3, IRAK3 | PLAU 4266/4885HRH3 1892/4885MAPK14 507/4885 |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | PLAU 4000/4885HRH3 2293/4885MAPK14 193/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | PLAU 4266/4885HRH3 1892/4885MAPK14 507/4885 |
| US-20190134010-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, IRAK2, JAK2 | PLAU 4476/4885HRH3 2417/4885MAPK14 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.